Healthcare Equipment and Supplies
Company Overview of Veracyte, Inc.
Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2006
Key Executives for Veracyte, Inc.
Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.
Veracyte, Inc. Key Developments
Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma® Gene Expression Classifier
Jan 22 16
Veracyte, Inc. announced that data demonstrating the ability of the Afirma Gene Expression Classifier (GEC) to reduce thyroid surgeries during three years of follow-up were published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists (AACE). The study provides the longest-term follow-up information published to date for the genomic test, which is used to identify patients whose thyroid nodules are benign following inconclusive fine needle aspiration (FNA) biopsy results, so that they can potentially avoid unnecessary diagnostic surgery and be monitored with ultrasound imaging instead. Researchers assessed surgery rates for patients with benign Afirma GEC results who were tested at 16 community-based practices across the United States and were followed for 36 months. They found that 82.7% of patients (81 out of 98) with a benign Afirma GEC result avoided surgery during the follow-up period, with the majority (88%) of any surgeries occurring within the first two years. In comparison, the historical rate of surgery avoidance is just 26% among thyroid nodule patients with indeterminate cytopathology results.
Veracyte, Inc. Announces Expansion to New South San Francisco Facility
Jan 7 16
Veracyte, Inc. announced that the company is relocating to expanded laboratory and corporate space within South San Francisco. The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.
Veracyte, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 11:00 AM
Dec 21 15
Veracyte, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 11:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 22, 2015